Sean Mackay insider trades: Standard Biotools (LAB) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Sean reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 23, 2025 | LAB | ↓ Sell | 13,217 | $0.94 | $12K | Direct | May 28, 2025 (5d) |
| May 22, 2025 | LAB | ↓ Sell | 25,374 | $1.02 | $26K | Direct | May 23, 2025 (1d) |
| Aug 25, 2022 | ISO | ↑ Buy | 15,000 | $1.99 | $30K | Direct | Aug 29, 2022 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other LAB insiders
Open-market trades in the last 12 months
About Sean Mackay's insider trades
Sean Mackay is SVP & Chief Business Officer at Standard Biotools (LAB). Since Aug 25, 2022, Sean has reported 1 open-market purchase worth $30K and 2 sales worth $38K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include shares withheld for taxes (6 filings), grants and awards (4 filings), shares returned to the company (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every LAB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.